Yumanity Shares Fall On FDA Hold On Multidose Trials In Parkinson's Disease

The FDA has placed a partial clinical hold on Yumanity Therapeutics Inc's YMTX multidose clinical trials of YTX-7739, currently being developed for Parkinson's disease.

•  The FDA has not halted all clinical programming and permits the Company's planned single-dose clinical trial to proceed. 
• The partial clinical hold suspends the initiation of multiple-dose clinical trials in the U.S. until the FDA's questions have been addressed.
• Related: Yumanity Therapeutics Stock Plunges After Parkinson's Trial Data.
• The Company expects to receive additional detail from the FDA within the next 30 days.
• Related content: Benzinga's Full FDA Calendar.
• YTX-7739 is Yumanity Therapeutics' proprietary lead small molecule investigational therapy designed to penetrate the blood-brain barrier and inhibit the activity of a novel target, stearoyl-CoA desaturase. 
• Price Action: YMTX shares are down 20.4% at $1.95 during the market session on the last check Wednesday.